

## HEMATOLOGICAL MALIGNANCIES RESEARCH HORIZONS

March 1<sup>st</sup> 2022 – Tel Aviv University

- 08:00 – 08:45**      **Registration and Reception**
- 09:00 – 09:30**      **Greetings and Ceremony**  
Prof. Ariel Porat - President of Tel Aviv University  
Prof. Ehud Grossman - Dean Sackler Faculty of Medicine  
Prof. Dan Peer - Vice President for Research & Development  
Prof. Shai Izraeli – Chair, the Varda and Boaz Dotan Center for Hemato-Oncology Research
- 09:30 – 10:15**      **Session I: Plenary**  
Chair: Shai Izraeli
- 09:30 – 10:15**      Translational Research in Blood Cancers - the Vision of City of Hope  
**Steven T. Rosen**, City of Hope National Medical Center
- 10:15 – 12:00**      **Session II: Myeloid Malignancies**  
Chairs: Yishai Ofran, Martin Ellis
- 10:15 – 10:35**      Mechanisms of Competition Between Healthy and Malignant Hematopoiesis  
**Cristina Lo Celso**, Imperial College London
- 10:35 – 10:50**      Regulation of DNA Damage Response in Normal and Leukemic Blood Stem Cell  
**Michael Milyavsky**, Sackler Faculty of Medicine
- 10:50 – 11:05**      From a Fortuitous Discovery to Treatment of AML  
**Shai Izraeli**, Schneider Children's Medical Center Israel
- 11:05 – 11:20**      Epitranscriptomics - From Basic Research to Leukemia Therapy



- Gidi Rechavi**, Sheba Medical Center, Tel Hashomer
- 11:20 – 11:40** RNA Methylation and the Regulators of Cellular Fate.
- Michael G. Kharas**, Memorial Sloan Kettering Cancer Center
- 11:40 – 12:00** **Discussion**
- 12:00 – 12:20** **Coffee break**
- 12:20 – 13:40** **Session III: Immunotherapies and Targeted Therapies**  
**Chairs: Drorit Neumann, Irit Avivi**
- 12:20 – 12:35** Therapeutic Gene Manipulation in Multiple Myeloma.  
**Dan Peer**, Faculty of Life Sciences, Tel Aviv University
- 12:35 – 12:50** CAR-T cells and CNS Leukemia  
**Elad Jacoby**, Sheba Medical Center, Tel Hashomer
- 12:50 – 13:05** A Unique Engineered T Cell Enables Antibody-Mediated Cytotoxicity to Overcome the Limitations of CAR T Cell Therapy  
**Yaron Carmi**, Sackler Faculty of Medicine
- 13:05 – 13:20** Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated with CD19 - Chimeric Antigen Receptor T-Cell Therapy  
**Roni Shouval**, Memorial Sloan Kettering Cancer Center
- 13:20 – 13:40** **Discussion**
- 13:40 – 14:30** **Lunch break**
- 14:30 – 15:00** **Session IV: Plenary**  
**Chair: Abraham Avigdor**
- 14:30 – 15:00** Targeting the Microenvironment in Lymphoid Malignancies



**15:00 – 16:25**

**Session V: Lymphoid Malignancies**

**Chairs: Pia Raanani, Moshe Gat**

**15:00 – 15:20**

B-Precursor ALL in Children: Prevention is Better than Cure

**Arndt Borkhardt**, University Hospital, Heinrich-Heine-University,  
Düsseldorf

**15:20 – 15:35**

Leveraging on Single Cell RNA-Sequencing and AI Technologies Towards  
Personalized Therapy in Myeloma.

**Yael Cohen**, Tel Aviv Sourasky Medical Center

**15:35 – 15:50**

Reprogramming of Bone Marrow Mesenchymal Stem Cells:  
Next Frontier in Myeloma Progression Markers

**Liat Drucker**, Meir Medical Center

**15:50 – 16:05**

B-Cell Receptor Spatial Organization, Early Signaling and  
its Targeting in CLL

**Yair Herishanu**, Tel Aviv Sourasky Medical Center

**16:05 – 16:25**

**Discussion and Concluding Remarks**

